VIENNA, Va., May 14 /PRNewswire-FirstCall/ -- CEL-SCI CORPORATION
(Amex: CVM) announced that Geert Kersten, Chief Executive Officer, will be
presenting at the Rodman & Renshaw 4th Annual Global Healthcare Conference
being held at Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco from May
14-15, 2007. The presentation will be focused on its Phase III cancer
product Multikine(R) which is the first biotech cancer product seeking to
become a new first line standard of care treatment in cancer.
Mr. Kersten's presentation will be on Tuesday, May 15th, at 11:10 a.m.
local time or 5:10 a.m. EDT. The presentation will be webcast live with
slides and archived for 90 days after the conference. The webcast can be
accessed at http://www.cel-sci.com.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has received the go-ahead
from the U.S. FDA and the Canadian Regulators to conduct a Phase III
clinical trial in advanced primary head and neck cancer patients with its
lead product Multikine. CEL-SCI's other products, which are currently in
pre-clinical stage and have been funded with U.S. government support, have
shown protection against a number of diseases in animal tests and are
currently being tested against diseases associated with bio-defense and
avian flu. The Company has operations in Vienna, Virginia and Baltimore,
Maryland.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
